Patents by Inventor Stephan D. Parent

Stephan D. Parent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230029213
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Application
    Filed: December 12, 2019
    Publication date: January 26, 2023
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • Publication number: 20220395492
    Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Application
    Filed: August 10, 2022
    Publication date: December 15, 2022
    Inventors: Zhe Li, Stephan D. Parent, Travis Houston
  • Publication number: 20220371994
    Abstract: A crystalline polymorphic form of psilocin is disclosed. The beneficial and therapeutic uses of the crystalline form and of compositions containing the crystalline form are also disclosed. The disclosure sets out methods of making and characterizing the crystalline form.
    Type: Application
    Filed: May 5, 2022
    Publication date: November 24, 2022
    Inventors: Nate Schultheiss, Travis Lee Houston, Stephan D. Parent
  • Publication number: 20220363674
    Abstract: Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Application
    Filed: May 13, 2022
    Publication date: November 17, 2022
    Inventors: Stephan D. Parent, Travis Lee Houston, Courtney S. Johnson, Fang Wang
  • Patent number: 11479557
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: October 25, 2022
    Assignee: VITAE PHARMACEUTICALS, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • Patent number: 11452720
    Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: September 27, 2022
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Stephan D. Parent, Travis Houston
  • Publication number: 20220289675
    Abstract: An object of the present invention is to provide a compound with an improved balance of S1P5 receptor agonist activity with respect to S1P1 receptor, and a form suitable for drug substances of pharmaceuticals. Provided is Compound I having high S1P5 receptor-selective agonist activity on the S1P1 receptor. In addition, the crystal forms of Compound I, the salts of Compound I, and the crystal forms of salts thereof disclosed in the present invention are provided as drug substances of pharmaceuticals.
    Type: Application
    Filed: August 19, 2020
    Publication date: September 15, 2022
    Applicant: ONO PHARMACEUTICALCO.,LTD.
    Inventors: Shuhei OTANI, Takayuki FUJITO, Naoko IMURA, Hideomi KIJIMA, Stephan D. PARENT, Melanie Janelle BEVILL, Courtney S. JOHNSON, Travis Lee HOUSTON
  • Publication number: 20220235045
    Abstract: The present invention provides a crystalline form and stable salts of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1- piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several hydrochloride salt forms, phosphate salt form, mesylate salt form, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Application
    Filed: May 20, 2020
    Publication date: July 28, 2022
    Inventors: Mary CHAVES, Ron C. KELLY, Prashant AGARWAL, Stephan D. PARENT, Darren Leonard REID, Roman SHIMANOVICH
  • Patent number: 11173156
    Abstract: Forms of 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I and salts or co-crystals thereof.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: November 16, 2021
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Vinod Khetarpal, Travis Lee Houston, Stephan D. Parent, Jian-xie Chen, Charles H. Montgomery, Geetha Banda
  • Patent number: 11028050
    Abstract: Provided herein are free base crystalline forms and crystalline salts of Compound 1.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: June 8, 2021
    Assignee: TETRA DISCOVERY PARTNERS, INC.
    Inventors: Mark E. Gurney, Jon P. Lawson, Stephan D. Parent, Richard James Ely
  • Publication number: 20210161876
    Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Application
    Filed: July 8, 2020
    Publication date: June 3, 2021
    Inventors: Zhe Li, Stephan D. Parent, Travis Houston
  • Publication number: 20210053974
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: April 1, 2020
    Publication date: February 25, 2021
    Applicant: VITAE PHARMACEUTICALS, LLC
    Inventors: Salvacion CACATIAN, David A. CLAREMON, Lawrence Wayne DILLARD, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Andrew MARCUS, Angel MORALES-RAMOS, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG, Stephan D. PARENT, Travis L. HOUSTON
  • Publication number: 20200397782
    Abstract: Forms of 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I and salts or co-crystals thereof.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 24, 2020
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Vinod Khetarpal, Travis Lee Houston, Stephan D. Parent, Jian-xie Chen, Charlie Montgomery, Geetha Banda
  • Publication number: 20200331858
    Abstract: Provided herein are free base crystalline forms and crystalline salts of Compound 1.
    Type: Application
    Filed: April 17, 2020
    Publication date: October 22, 2020
    Inventors: Mark E. Gurney, Jon P. Lawson, Stephan D. Parent, Richard James Ely
  • Patent number: 10722502
    Abstract: Disclosed are crystalline free base an solvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: July 28, 2020
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Stephan D. Parent, Travis Houston
  • Patent number: 10683302
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 16, 2020
    Assignee: VITAE PHARMACEUTICALS, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • Publication number: 20190255031
    Abstract: Disclosed are crystalline free base an solvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Application
    Filed: October 18, 2018
    Publication date: August 22, 2019
    Inventors: Zhe Li, Stephan D. Parent, Travis Houston
  • Publication number: 20190144459
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 16, 2019
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • Patent number: 10137118
    Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: November 27, 2018
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Stephan D. Parent, Travis Houston
  • Publication number: 20180289686
    Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Application
    Filed: November 1, 2017
    Publication date: October 11, 2018
    Inventors: Zhe Li, Stephan D. Parent, Travis Houston